Melanoma in the brain: Biology and therapeutic options

Melanoma Research

Volumn 22, Issue 3, 2012, Pages 177-183

  Gibney, Geoffrey Thomas ^a,b   Forsyth, Peter A ^a,b   Sondak, Vernon K ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Biology; BRAF brain metastasis; Ipilimumab; Melanoma; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; IPILIMUMAB; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; THALIDOMIDE; VEMURAFENIB;

BRAIN METASTASIS; CANCER RECURRENCE; CANCER SURGERY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; MELANOMA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SEIZURE; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CRANIAL IRRADIATION; HUMANS; IMMUNOTHERAPY; MELANOMA; NEUROSURGICAL PROCEDURES; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS; THERAPEUTICS;

EID: 84860734031     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328352dbef     Document Type: Review

References (63)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
2. Sampson JH, Carter JH Jr., Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11-20. (Pubitemid 28018958)
3. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011; 117:1711-1720.
4. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239-1246.
5. Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996; 3:118-123. (Pubitemid 126729498)
6. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293-1300. (Pubitemid 41079844)
7. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011; 117:1697-1703.
8. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218.
9. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 2002; 94:2265-2272. (Pubitemid 34411986)
10. Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011; 21:107-112.
11. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA 2010; 107:21677-21682.
12. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 2011; 8:344-356.
13. Denkins Y, Reiland J, Roy M, Sinnappah-Kang ND, Galjour J, Murry BP, et al. Brain metastases in melanoma: roles of neurotrophins. NeuroOncol 2004; 6:154-165. (Pubitemid 38455762)
14. Izraely S, Klein A, Sagi-Assif O, Meshel T, Tsarfaty G, Hoon DS, et al. Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol Lett 2010; 130:107-114.
15. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 2009; 16:248-255.
16. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010; 16:116-122.
17. Nathoo N, Chahlavi A, Barnett GH, Toms SA. Pathobiology of brain metastases. J Clin Pathol 2005; 58:237-242. (Pubitemid 40380315)
18. Kusters B, Leenders WP, Wesseling P, Smits D, Verrijp K, Ruiter DJ, et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002; 62:341-345. (Pubitemid 34106399)
19. Kusters B, deWaal RM, Wesseling P, Verrijp K, Maass C, Heerschap A, et al. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res 2003; 63:5408-5413. (Pubitemid 37139858)
20. Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, et al. Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 2008; 68:9634-9642.
21. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res 2006; 66:3188-3196.
22. Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, et al. The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int J Cancer 2011[Epub ahead of print].
23. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2011; 123:223-233.
24. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, DeGiorgi V, et al. Prevalence of BRAF and NRAS mutations in primary tumours and different types of metastasis among melanoma patients. Pigment Cell Melanoma Res 2011; 24:SMR-P66.
25. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009; 15:7538-7546.
26. Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011; 24:666-672.
27. Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2007; 2:e236.
28. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010; 29:5545-5555.
29. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43:795-803. (Pubitemid 29152652)
30. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. National Comprehensive Cancer Network; 2011. Available at http://www. nccn. org/professionals/physician-gls/pdf/cns. pdf. [Accessed 24 January 2012].
31. Ewend MG, Morris DE, Carey LA, Ladha AM, Brem S. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Canc Netw 2008; 6:505-513.
32. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci 2000; 44:211-218.
33. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134-141.
34. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485-1489. (Pubitemid 28507400)
35. Alexander E III, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995; 87:34-40.
36. Flickinger JC, Kondziolka D, Lunsford LD, Coffey RJ, Goodman ML, Shaw EG, et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994; 28:797-802. (Pubitemid 24099860)
37. O'Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O'Fallon J.R. (Pubitemid 36338280)
38. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-1672. (Pubitemid 38670323)
39. Rades D, Panzner A, Dziggel L, Haatanen T, Lohynska R, Schild SE. Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 2011[Epub ahead of print].
40. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007; 6:650-661. (Pubitemid 47202487)
41. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010; 16:4892-4898.
42. Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 2009; 8: 892-909.
43. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22: 2101-2107. (Pubitemid 41095143)
44. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008; 113:2139-2145.
45. Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006; 76:59-64. (Pubitemid 43115761)
46. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005; 103:2590-2597. (Pubitemid 40800539)
47. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002; 128:214-218. (Pubitemid 34280379)
48. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125. (Pubitemid 41095046)
49. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003; 13:97-103. (Pubitemid 36269821)
50. Vestermark LW, Larsen S, Lindelov B, Bastholt L. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol 2008; 47:1526-1530.
51. Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, et al. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007; 96: 44-48. (Pubitemid 46094637)
52. Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 2002; 25:82-87. (Pubitemid 34052838)
53. Powell S, Dudek AZ. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res 2009; 29: 4189-4193.
54. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
55. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
56. Lawrence DP, Hamid O, McDermott DF, Puzanov I, Sznol M, Clark J, et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases [abstract]. J Clin Oncol 2010; 28 (15s):8523.
57. Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010; 20: 247-250.
58. Heller KN, Pavlick AC, Hodi FS, Thompson JA, Margolin KA, Lawrence DP, et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases [abstract]. J Clin Oncol 2011; 29:8581.
59. Di Giacomo AM, Ascierto PA, Fonsatti E, Pittiglio E, Queirolo P, Pilla L, et al. A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: the NIBIT-M1 trial [abstract]. J Clin Oncol 2011; 29:TPS230.
60. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
61. Kefford R, Arkenau H, Brown MP, Millward M, Infante J.R.
62. Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, Veronese ML, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases [abstract]. J Clin Oncol 2011; 29:8548.
63. Long GV, Kefford RF, Carr PJA, Brown MP, Curtis M, Ma B, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (MUT) BRAF kinase: evidence of activity in melanoma brain metastases (METS) [abstract]. Ann Oncol 2010; 21:viii12, LBA27.